| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440819 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
A modelling framework was established, quantitatively describing the tumour growth inhibitory effects of various gemcitabine combotherapies and the effect of the resulting CTS on survival in first-line mBC. This work further supports the use of early CTS as a go/no-go decision point during phase II clinical evaluation of treatments for mBC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sonya C. Tate, Valerie Andre, Nathan Enas, Benjamin Ribba, Ivelina Gueorguieva,